231 related articles for article (PubMed ID: 19043454)
1. In vitro and in vivo analysis of B-Myb in basal-like breast cancer.
Thorner AR; Hoadley KA; Parker JS; Winkel S; Millikan RC; Perou CM
Oncogene; 2009 Feb; 28(5):742-51. PubMed ID: 19043454
[TBL] [Abstract][Full Text] [Related]
2. ANCCA/ATAD2 overexpression identifies breast cancer patients with poor prognosis, acting to drive proliferation and survival of triple-negative cells through control of B-Myb and EZH2.
Kalashnikova EV; Revenko AS; Gemo AT; Andrews NP; Tepper CG; Zou JX; Cardiff RD; Borowsky AD; Chen HW
Cancer Res; 2010 Nov; 70(22):9402-12. PubMed ID: 20864510
[TBL] [Abstract][Full Text] [Related]
3. Central spindle proteins and mitotic kinesins are direct transcriptional targets of MuvB, B-MYB and FOXM1 in breast cancer cell lines and are potential targets for therapy.
Wolter P; Hanselmann S; Pattschull G; Schruf E; Gaubatz S
Oncotarget; 2017 Feb; 8(7):11160-11172. PubMed ID: 28061449
[TBL] [Abstract][Full Text] [Related]
4. B-myb is a gene implicated in cell cycle and proliferation of breast cancer.
Tao D; Pan Y; Lu H; Zheng S; Lin H; Fang H; Cao F
Int J Clin Exp Pathol; 2014; 7(9):5819-27. PubMed ID: 25337223
[TBL] [Abstract][Full Text] [Related]
5. DNA topoisomerase IIalpha (TOP2A) inhibitors up-regulate fatty acid synthase gene expression in SK-Br3 breast cancer cells: in vitro evidence for a 'functional amplicon' involving FAS, Her-2/neu and TOP2A genes.
Menendez JA; Vellon L; Lupu R
Int J Mol Med; 2006 Dec; 18(6):1081-7. PubMed ID: 17089011
[TBL] [Abstract][Full Text] [Related]
6. Isolation and functional assessment of common, polymorphic variants of the B-MYB proto-oncogene associated with a reduced cancer risk.
Schwab R; Bussolari R; Corvetta D; Chayka O; Santilli G; Kwok JM; Ferrari-Amorotti G; Tonini GP; Iacoviello L; Bertorelle R; Menin C; Hubank M; Calabretta B; Sala A
Oncogene; 2008 May; 27(20):2929-33. PubMed ID: 18026132
[TBL] [Abstract][Full Text] [Related]
7. B-MYB is required for recovery from the DNA damage-induced G2 checkpoint in p53 mutant cells.
Mannefeld M; Klassen E; Gaubatz S
Cancer Res; 2009 May; 69(9):4073-80. PubMed ID: 19383908
[TBL] [Abstract][Full Text] [Related]
8. c-Myb trans-activates the human DNA topoisomerase IIalpha gene promoter.
Brandt TL; Fraser DJ; Leal S; Halandras PM; Kroll AR; Kroll DJ
J Biol Chem; 1997 Mar; 272(10):6278-84. PubMed ID: 9045645
[TBL] [Abstract][Full Text] [Related]
9. Induction of sensitivity to doxorubicin and etoposide by transfection of MCF-7 breast cancer cells with heregulin beta-2.
Harris LN; Yang L; Tang C; Yang D; Lupu R
Clin Cancer Res; 1998 Apr; 4(4):1005-12. PubMed ID: 9563896
[TBL] [Abstract][Full Text] [Related]
10. Predictive value of topoisomerase IIalpha and other prognostic factors for epirubicin chemotherapy in advanced breast cancer.
Järvinen TA; Holli K; Kuukasjärvi T; Isola JJ
Br J Cancer; 1998 Jun; 77(12):2267-73. PubMed ID: 9649144
[TBL] [Abstract][Full Text] [Related]
11. The cell cycle regulatory DREAM complex is disrupted by high expression of oncogenic B-Myb.
Iness AN; Felthousen J; Ananthapadmanabhan V; Sesay F; Saini S; Guiley KZ; Rubin SM; Dozmorov M; Litovchick L
Oncogene; 2019 Feb; 38(7):1080-1092. PubMed ID: 30206359
[TBL] [Abstract][Full Text] [Related]
12. Contribution of c-erbB-2 and topoisomerase IIalpha to chemoresistance in ovarian cancer.
Hengstler JG; Lange J; Kett A; Dornhöfer N; Meinert R; Arand M; Knapstein PG; Becker R; Oesch F; Tanner B
Cancer Res; 1999 Jul; 59(13):3206-14. PubMed ID: 10397267
[TBL] [Abstract][Full Text] [Related]
13. Amplification and deletion of topoisomerase IIalpha associate with ErbB-2 amplification and affect sensitivity to topoisomerase II inhibitor doxorubicin in breast cancer.
Järvinen TA; Tanner M; Rantanen V; Bärlund M; Borg A; Grénman S; Isola J
Am J Pathol; 2000 Mar; 156(3):839-47. PubMed ID: 10702400
[TBL] [Abstract][Full Text] [Related]
14. Clinical and Genomic Implications of Luminal and Basal Subtypes Across Carcinomas.
Zhao SG; Chen WS; Das R; Chang SL; Tomlins SA; Chou J; Quigley DA; Dang HX; Barnard TJ; Mahal BA; Gibb EA; Liu Y; Davicioni E; Duska LR; Posadas EM; Jolly S; Spratt DE; Nguyen PL; Maher CA; Small EJ; Feng FY
Clin Cancer Res; 2019 Apr; 25(8):2450-2457. PubMed ID: 30573691
[TBL] [Abstract][Full Text] [Related]
15. B-Myb Mediates Proliferation and Migration of Non-Small-Cell Lung Cancer via Suppressing IGFBP3.
Fan X; Wang Y; Jiang T; Cai W; Jin Y; Niu Y; Zhu H; Bu Y
Int J Mol Sci; 2018 May; 19(5):. PubMed ID: 29772705
[TBL] [Abstract][Full Text] [Related]
16. The role of MYB proto-oncogene like 2 in tamoxifen resistance in breast cancer.
Li X; Zhang X; Wu CC; Li PP; Fu YM; Xie LH; Sun SS; Zhou YY; Zhu BL
J Mol Histol; 2021 Feb; 52(1):21-30. PubMed ID: 33141360
[TBL] [Abstract][Full Text] [Related]
17. The Myb-MuvB Complex Is Required for YAP-Dependent Transcription of Mitotic Genes.
Pattschull G; Walz S; Gründl M; Schwab M; Rühl E; Baluapuri A; Cindric-Vranesic A; Kneitz S; Wolf E; Ade CP; Rosenwald A; von Eyss B; Gaubatz S
Cell Rep; 2019 Jun; 27(12):3533-3546.e7. PubMed ID: 31216474
[TBL] [Abstract][Full Text] [Related]
18. c-erbB2 and topoisomerase IIalpha protein expression independently predict poor survival in primary human breast cancer: a retrospective study.
Fritz P; Cabrera CM; Dippon J; Gerteis A; Simon W; Aulitzky WE; van der Kuip H
Breast Cancer Res; 2005; 7(3):R374-84. PubMed ID: 15987433
[TBL] [Abstract][Full Text] [Related]
19. B-Myb Is Up-Regulated and Promotes Cell Growth and Motility in Non-Small Cell Lung Cancer.
Jin Y; Zhu H; Cai W; Fan X; Wang Y; Niu Y; Song F; Bu Y
Int J Mol Sci; 2017 May; 18(6):. PubMed ID: 28555007
[TBL] [Abstract][Full Text] [Related]
20. Expression of A-myb, but not c-myb and B-myb, is restricted to Burkitt's lymphoma, sIg+ B-acute lymphoblastic leukemia, and a subset of chronic lymphocytic leukemias.
Golay J; Luppi M; Songia S; Palvarini C; Lombardi L; Aiello A; Delia D; Lam K; Crawford DH; Biondi A; Barbui T; Rambaldi A; Introna M
Blood; 1996 Mar; 87(5):1900-11. PubMed ID: 8634438
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
